南昌治抑郁方法哪个有效南昌到哪治疗焦虑症,南昌市第十二医院看精神科靠不靠谱口碑咋样,南昌幻听中医怎样治,南昌第十二医院专业嘛口碑如何,南昌哪个医院的抑郁症较好,南昌那有治焦虑的,南昌市治听幻医院那家比较好

With nearly twice the number of unemployed Americans compared to this time last year, the competition for seasonal work is more stiff.But some of America’s largest companies are looking to make significant additions to their workforce heading into a unique and challenging holiday season. And for some companies, they’re planning on making some or all of their new hires permanent employees.If you’re in need of a job, here are a few companies seeking help:1-800 Flowers Inc.1-800 Flowers Inc. announced earlier this month plans on hiring 10,000 seasonal workers to assist with its delivery service. The majority of these roles are being offered throughout Illinois, Ohio and Oregon, with some work-from-home positions available, the company said.7-ElevenConvenience store chain 7-Eleven announced Monday it plans on hiring 20,000 new permanent associates throughout the US. The chain has bolstered its staff as it has expanded its delivery service amid the pandemic.AmazonOnline retailer Amazon announced plans on hiring 100,000 associates in the US and Canada to bolster its staff for the holidays. The positions are permanent and are both part-time and full-time. The positions have a starting wage of an hour, and Amazon is offering a ,000 “signing bonus” in some locales.FedExThe delivery service said last week it plans on hiring 70,000 workers between now and the end of the year. FedEx said that many of these positions will be used to bolster its ground service.UPSDelivery service UPS said that it plans to hire 100,000 seasonal workers this year as the company sees an influx of deliveries between October and January. The positions will be both part-time and full-time.UPS says that in the past, one-third of its seasonal workforce is hired permanently.This story will be updated as companies announce seasonal hiring plans. 1850

With just over a month until the election, Florida and Arizona are emerging as battleground states that are neck-and-neck for President Donald Trump and former vice president Joe Biden.For the first time in 2020, Trump has a slight lead in Florida, according to the Washington Post-ABC News poll. Among participants who said they are likely voters, Trump leads 51-to-47 percent, however this is considered within the margin of error.The poll points out Biden has a 13-point lead among Hispanic registered voters in Florida; four years ago, Hillary Clinton had a 27-point lead among Hispanics and still lost the state.In Arizona, among likely voters, the poll shows Trump and Biden at 49-to-48 percent. Arizona has voted for the Republican presidential candidate for every election since 1952 except once, the re-election of Bill Clinton in 1996.Researchers of this poll note that these percentages are so close the difference is not statistically significant. The margin of sampling error is 4 points among Florida results and 4.5 points among Arizona results.Trump won Florida and Arizona in the last election. In Arizona, Trump won in 2016 by about 90,000 votes. In Florida, Trump won by just over 100,000 votes.When it comes to the issues, Trump gets credit for being trusted to handle the economy, despite the current pandemic-fueled recession. In Florida, registered voters in the survey said they trusted Trump with the economy over Biden 52-to-41 percent. In Arizona, the spread is higher, with registered voters preferring Trump 56-to-41 percent.The economy appears to be the top issue for many this election cycle. About 31 percent of registered voters in Florida said the economy is the single most important issue, and 33 percent of those in Arizona.In handling the coronavirus pandemic, more registered voters trust Biden over Trump, with 48-to-43 percent in Florida and 49-to-45 percent in Arizona. In both states, 57 percent of participants said they were worried about catching the coronavirus.Biden also leads in handling health care, crime and safety, discouraging violence at political protests, and equal treatment of racial groups.Trump’s overall approval rating among registered voters is 47 percent in both states.There is also a big split in how voters of different parties plan to vote on Election Day. In both Florida and Arizona, more than 70 percent of registered Republicans plan on voting in-person on Election Day. Democratic participants are more likely to vote early or absentee/mail-in, more than 60 percent.This latest poll was conducted by landline and cell phone interviews between September 15-20 among 765 registered Florida voters and 701 registered Arizona voters. 2712

While there are still questions about whether trick-or-treating will happen in 2020 and how neighborhoods will make it possible, there is no question Americans like their Halloween candy.Sales of Halloween candy and chocolate at grocery stores are up 17 percent over 2019 so far this season, according to the National Confectioners Association. Total sales, including online purchases, is up 13 percent year-over-year.The National Confectioners Association, NCA, represents manufacturers and suppliers of sweet treats, gum, mints and chocolates.Their research showed chocolate is driving the increase. Halloween chocolate sales are up 25 percent over 2019 so far. The NCA released data over the summer showing chocolate was the treat of choice of Americans during the pandemic, with sales increasing five percent March through August over the same time period in 2019. Sales of premium chocolate during that time was up 12 percent year-over-year. Ferrara Candy, which makes Sweetarts, Nerds, Brach’s Candy Corn, Gobstoppers and more, said Halloween sales bring in about .5 billion in sales. In an interview with Axios, CEO Todd Siwak said their company learned a lot from the drop in sales for Easter. This was also the time many stores were closing because of lockdowns to stop the spread of the coronavirus. Even as shopping has picked up a little, they have made some changes.“As the frequency in-store is reduced by the shopper, so fewer trips but bigger baskets, we wanted to make sure we were there presenting the opportunity to consumers,” Siwak said. He added Ferrara Candy created more individually-wrapped confections and got product to stores earlier to extend the selling season.There are still about three weeks until Halloween, and the industry expects sales to increase. Siwak says about 60 percent of the sales for Halloween candy happen in the last few weeks before the holiday.The NCA data also suggested Americans are getting more excited for Halloween in 2020. They found 80 percent believe they will find creative and safe ways to celebrate this year. The response was just 63 percent in July. 2125

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

WILMINGTON, Del. – President-elect Joe Biden received his initial dose of the coronavirus vaccine on Monday.Biden received his Pfizer-BioNTech vaccine at ChristianaCare Hospital and it was administered by Tabe Mase, a nurse practitioner and head of employee health services at the hospital.With his wife, Jill, by his side, Biden received the vaccination in front of cameras as part of a growing effort to show Americans that the vaccines are safe and necessary for the nation to emerge from the pandemic.Watch Biden get vaccinated below:After he received his dose of the vaccine, Biden said his wife received her vaccination earlier in the day.“I’m doing this to demonstrate that people should be prepared when it’s available to take the vaccine. There’s nothing to worry about. I’m looking forward to the second shot and so is Jill. She’s had her shot earlier today,” said Biden.Biden said the Trump administration deserves some credit for getting the vaccine production off the ground with Operation Warp Speed.The former vice president went on to urge the public to continue taking the necessary precautions to prevent the spread of the coronavirus, because we’re still in the middle of a surge in cases.He also mentioned Moderna in his remarks, which began distributing its COVID-19 vaccine on Monday.“It’s worth stating that this is just the beginning,” said Biden. “It’s one thing to get the vaccine out. And now Moderna is going to be on the road as well, but it’s going to take time. In the meantime, I know I don’t want to sound like a sour note here, but I hope people listen to all the experts, who are talking about the need to wear masks during the Christmas and New Year’s holidays, social distance, and if you don’t have to travel, don’t travel, because we’re still in the thick of this.”Biden joins a growing list of lawmakers who have now received their first doses of the COVID-19 vaccine. Vice President Mike Pence, House Speaker Nancy Pelosi and Senate Majority Leader Mitch McConnell were among those were given doses Friday.President Donald Trump hasn't yet received the vaccine or said when he intends to. 2137